AstraZeneca Launches At-Home FluMist
Digest more
AstraZeneca (LSE:AZN) recently launched "FluMist Home," an at-home flu vaccine delivery service, marking an important milestone for easier access to vaccinations in 34 U.S. states. This initiative likely contributed to its stock price increase of 12% last quarter,
FluMist has been approved since 2003, but, until last year, only for administration by a healthcare practitioner. The new nod allows adults up to 49 years old to use the nasal spray themselves, while parents and caregivers can give it to children aged 2 to 17.